Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLA and Flavonifractor in liver cirrhosis
2022-002924-11Phase 4Completed
- Sponsor
- CBmed
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of l-ornithine l-aspartate in Cirrhosis and hepatic encephalopathy (HE), sponsored by CBmed. Primary endpoint: Increase of the genus Flavonifractor in the gut microbiome after 3 months of LOLA treatment. Started Jan 2023; status: completed.
02
Drugs
l-ornithine l-aspartate
03
Conditions
Cirrhosishepatic encephalopathy (HE)
Beyond the preview
Go deeper on 2022-002924-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002924-11.